Radar · Life Sciences in Germany
Best Life Sciences Companies in Germany
The 1802 best Life Sciences companies in Germany in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: CureVac.
By Riya SenguptaFinancials
1802companies tracked
$10.9Bdisclosed funding
2unicorns
545have raised
Germany's Life Sciences sector has 1,802 companies on our radar, carrying $10.9B in total disclosed funding and two unicorns in the mix. That's a real capital base. ITM leads the field at $681M raised, with Tubulis Technologies at $214M and Vivoryon at $112M showing that serious money is moving well beyond the headline name. Hot themes right now are cell-based therapies, stem cell banking, and gene delivery systems, while healthcare and life sciences apps are clocking median install growth of roughly 43% year-on-year, so the digital layer of this industry is expanding as fast as the lab side. Europa, HTGF, and EIC Fund are the most active investors here, if you're mapping the capital network.
The global life sciences market sits at approximately $167.8B with a 10.2% CAGR, and Germany's cluster punches well within that growth curve. Aging population tailwinds and strong public funding keep deal flow moving. I'd note that coverage breadth stays relatively flat even as specific niches, diagnostic biotechnology especially, attract disproportionate attention. What separates the serious contenders here from the noise? Disclosed funding with actual momentum behind it, which is exactly what this directory ranks.
Sources & further reading
- How India is Becoming a Global Leader in Biotech Innovation and Research
- Split-brain Research: Even Minimal Fiber Links Can Unify Consciousness
- Morgan Stanley Ups the Ante on These 2 Life Science Tool Stocks
FLIAR INTELLIGENCE · LIFE SCIENCES × GERMANY
Our analysis of 50 Life Sciences companies
$3.3b in tracked funding; 51% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2024.
50companies analysed
51%cloud-native stacks
2024funding peak (by rounds)
2016median founding year
40median Fliar Index™
764kcombined LinkedIn audience
75%of audience held by top 3
3companies hiring publicly (12 mo)
Ranked: Best Life Sciences companies in Germany
| # | Company | Disclosed funding | Last round | Employees | Founder | Tech stack | Market signals (1y) | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | BioNTech Developer of immunotherapeutics for the treatment of cancer and other diseases 78Patents top 7%Innovation top 17%News top 26%Tech top 28% All 13 signals ▾Patentstop 7% Innovationtop 17% Newstop 26% Techtop 28% Globaltop 28% Fundingtop 29% Talenttop 29% Growthtop 33% Moattop 35% Producttop 39% Markettop 48% Partnersbottom 43% Fin. healthbottom 42% Patents: 2,228 patents matched (strict assignee match) · 1521 filings since 2022 vs 431 in 2017-21 Innovation: 2,228 patents (top 1% of patent-holders) · 1521 filings since 2022 vs 431 in 2017-21 rank vs industry peers · Fliar Intelligence Index 78/100 | $806M | 50 mo ago | 4,530 4,530 → 5,204 (+15%) | Christoph Huber Co-Founder & Managing Director | TurbopackSentryNode.js+19 | 26 signals Leadership · Announcements · M&A | 2,228 patents mRNA vaccine formulation, nucleic acid therapeutics, and immune‑checkpoint cancer combo technologies | 1 partnership |
| 2 | ITM Developer of radiopharmaceuticals and radioisotopes for cancer treatment 27Funding top 25%Growth top 35%Moat top 42%Global top 48% All 9 signals ▾Fundingtop 25% Growthtop 35% Moattop 42% Globaltop 48% Talenttop 50% Marketbottom 38% Techbottom 26% Newsbottom 20% Fin. healthbottom 10% Funding: Raised $681M across 8 rounds · 8 rounds over 17 yrs (0.5/yr) Growth: Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 27/100 | $681M | 12 mo ago | 54 | Oliver Buck Founder | TYPO3 CMSPHPBootstrap+8 | — | — | 1 award |
| 3 | CatalYm Developer of drugs for the treatment of cancer 37Funding top 24%Moat top 28%Patents top 42%Innovation top 45% All 9 signals ▾Fundingtop 24% Moattop 28% Patentstop 42% Innovationtop 45% Growthtop 48% Globalbottom 39% Marketbottom 33% Techbottom 33% Newsbottom 17% Funding: Raised $261M across 3 rounds · 3 rounds over 10 yrs (0.3/yr) Moat: Editorial + unicorn rating 8/10 · IP moat: 23 patents rank vs industry peers · Fliar Intelligence Index 37/100 | $261M | 23 mo ago | 18 | — | WordPressApple iCloud MailMicrosoft 365+20 | — | 23 patents Therapeutic anti‑GDF15 antibodies for neoadjuvant and combination cancer treatment | — |
| 4 | Immatics Developer of T -cell-based immunotherapies for the treatment of cancer 76Product top 14%Funding top 23%News top 23%Patents top 30% All 10 signals ▾Producttop 14% Fundingtop 23% Newstop 23% Patentstop 30% Techtop 31% Growthtop 32% Moattop 32% Innovationtop 39% Markettop 41% Globaltop 50% Product: 6 distinct product lines · Company stage: Public Funding: Raised $236M across 7 rounds · 7 rounds over 22 yrs (0.3/yr) rank vs industry peers · Fliar Intelligence Index 76/100 | $236M | 34 mo ago | 198 | — | WordPressApple iCloud MailMicrosoft 365+31 | 9 signals ▲80% Leadership · Funding · Earnings | 43 patents Engineering and selection of antigen-specific T cells for adoptive immunotherapy | — |
| 5 | Tubulis Technologies Developer of antibody-drug conjugates for the treatment of cancer 60News top 15%Funding top 18%Growth top 20%Patents top 27% All 10 signals ▾Newstop 15% Fundingtop 18% Growthtop 20% Patentstop 27% Moattop 28% Innovationtop 35% Talenttop 50% Marketbottom 42% Globalbottom 42% Techbottom 32% News: 13 BI events in 12 mo (of 21 tracked, 3 types) · +333% YoY Funding: Raised $214M across 5 rounds · 5 rounds over 6 yrs (0.8/yr) rank vs industry peers · Fliar Intelligence Index 60/100 | $214M | 8 mo ago | 33 | Dominik Schumacher Co-Founder & CEO | WordPressMySQLPHP+14 | 13 signals ▲333% M&A · Funding · Leadership | 70 patents Phosphorus‑based linkers for antibody‑drug conjugates targeting cancer antigens | — |
| 6 | Vivoryon Developer of therapeutic agents for age related disorders 45Funding top 19%News top 29%Growth top 47%Market top 49% All 7 signals ▾Fundingtop 19% Newstop 29% Growthtop 47% Markettop 49% Talentbottom 49% Globalbottom 39% Techbottom 29% Funding: Raised $112M across 5 rounds · 5 rounds over 11 yrs (0.5/yr) News: 4 BI events in 12 mo (of 6 tracked, 3 types) · Top themes: Earnings, Funding rank vs industry peers · Fliar Intelligence Index 45/100 | $112M | 8 mo ago | 100 | Ulrich Dauer CEO | WordPressMySQLPHP+13 | 4 signals Earnings · Funding | — | — |
| 7 | TRiCares Developer of a minimally invasive tricuspid valve replacement system. 27Funding top 21%Growth top 35%Moat top 36%Global bottom 47% All 9 signals ▾Fundingtop 21% Growthtop 35% Moattop 36% Globalbottom 47% Patentsbottom 42% Innovationbottom 36% Marketbottom 27% Techbottom 21% Newsbottom 18% Funding: Raised $103M across 5 rounds · 5 rounds over 8 yrs (0.6/yr) Growth: Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 27/100 | $103M | 4 mo ago | 12 | — | DrupalPleskPHP+3 | — | 3 patents Patents concentrated in health & consumer products | — |
| 8 | Biofrontera Developer of therapies for actinic keratosis using photodynamic therapy 50Market top 29%Funding top 30%News top 34%Moat top 48% All 8 signals ▾Markettop 29% Fundingtop 30% Newstop 34% Moattop 48% Fin. healthtop 50% Growthbottom 43% Globalbottom 43% Techbottom 30% Market: 149 employees (top 13% of Life Sciences) · Revenue ~$41.7M Funding: Raised $93.4M across 10 rounds · 10 rounds over 22 yrs (0.5/yr) rank vs industry peers · Fliar Intelligence Index 50/100 | $93M | 27 mo ago | 149 | — | — | 11 signals Earnings · Acquisition · Regulatory | — | — |
| 9 | Medigene Developer of T cell immunotherapies for haematological malignancies 62Product top 14%Patents top 32%Funding top 34%Innovation top 37% All 12 signals ▾Producttop 14% Patentstop 32% Fundingtop 34% Innovationtop 37% Fin. healthtop 38% Growthtop 40% Moattop 41% Markettop 42% Partnerstop 45% Techbottom 44% Globalbottom 44% Newsbottom 26% Product: 5 distinct product lines · Company stage: Public Patents: 341 patents matched (strict assignee match) · 4 filings since 2022 vs 46 in 2017-21 rank vs industry peers · Fliar Intelligence Index 62/100 | $82M | 25 mo ago | 114 | — | WordPressMySQLPHP+18 | — | 341 patents Patents concentrated in health & consumer products | — |
| 10 | SciRhom Developer of drugs for treating autoimmune disease 40Moat top 31%Patents top 32%Funding top 34%Talent top 38% All 8 signals ▾Moattop 31% Patentstop 32% Fundingtop 34% Talenttop 38% Innovationtop 41% Globalbottom 44% Marketbottom 30% Newsbottom 18% Moat: Editorial + unicorn rating 4/10 · IP moat: 29 patents Patents: 29 patents matched (strict assignee match) · 23 filings since 2022 vs 6 in 2017-21 rank vs industry peers · Fliar Intelligence Index 40/100 | $79M | 23 mo ago | 12 | Matthias Schneider Co-Founder & CSO | — | — | 29 patents Therapeutic antibodies and inhibitors targeting iRhom2 for disease treatment | — |
| 11 | Aignostics Developer of artificial intelligence software for biomedical image analysis applications 64AI top 25%Growth top 26%Funding top 27%Talent top 28% All 11 signals ▾AItop 25% Growthtop 26% Fundingtop 27% Talenttop 28% Moattop 39% Innovationtop 47% Patentstop 47% Techbottom 49% Globalbottom 37% Marketbottom 35% Newsbottom 18% AI: Classified as an AI company · Holds AI/ML patents (G06N-family CPC) Growth: Headcount 10 → 25 (+150%) across vintages · Web rank 5,000,000 → 10,000,000 YoY rank vs industry peers · Fliar Intelligence Index 64/100 | $55M | 19 mo ago | 25 | Maximilian Alber Co-Founder & CTO | WebflowApple iCloud MailGoogle Workspace+18 | — | 5 patents AI-driven detection and classification of biological structures for medical imaging diagnostics | 1 partnership · 1 award |
| 12 | Protembis Manufacturer of cerebral protection device 29Moat top 25%Innovation top 32%Funding top 32%Patents top 35% All 7 signals ▾Moattop 25% Innovationtop 32% Fundingtop 32% Patentstop 35% Globalbottom 42% Newsbottom 21% Marketbottom 18% Moat: Editorial + unicorn rating 7/10 · IP moat: 59 patents Innovation: 59 patents (top 43% of patent-holders) · 34 filings since 2022 vs 22 in 2017-21 rank vs industry peers · Fliar Intelligence Index 29/100 | $42M | 22 mo ago | 3 | — | — | — | 59 patents Embolic protection devices for aortic arch during cardiovascular interventions | — |
| 13 | HepaRegeniX Developer of small molecule therapeutics 42Talent top 28%Patents top 29%Funding top 32%Innovation top 38% All 9 signals ▾Talenttop 28% Patentstop 29% Fundingtop 32% Innovationtop 38% Moattop 39% Globalbottom 44% Growthbottom 42% Marketbottom 29% Newsbottom 18% Talent: 4 named leaders on record · 4 C-suite/founder profiles curated Patents: 76 patents matched (strict assignee match) · 42 filings since 2022 vs 34 in 2017-21 rank vs industry peers · Fliar Intelligence Index 42/100 | $38M | 14 mo ago | 9 | Lars Zender Co-Founder | — | — | 76 patents Small-molecule kinase inhibitors for liver regeneration and cancer therapy targeting MKK4 and related kinases. | — |
| 14 | SphingoTec Developer of biomarker-based diagnostic solutions for cancer, cardiovascular, and other diseases 55Growth top 20%Moat top 21%Funding top 32%Patents top 35% All 10 signals ▾Growthtop 20% Moattop 21% Fundingtop 32% Patentstop 35% Talenttop 38% Innovationtop 41% Globalbottom 40% Marketbottom 38% Techbottom 32% Newsbottom 18% Growth: Headcount 23 → 36 (+57%) across vintages · Fresh capital in last 24 mo Moat: Editorial + unicorn rating 7/10 · IP moat: 264 patents rank vs industry peers · Fliar Intelligence Index 55/100 | $36M | 22 mo ago | 36 36 → 19 (-47%) | Andreas Bergmann Founder | Cart FunctionalityTYPO3 CMSPHP+13 | — | 264 patents Clinical biomarker assay development for kidney, sepsis, and neurodegenerative diagnostics | 4 launchs · 1 partnership |
| 15 | 4TEEN4 Pharmaceuticals Developer of therapeutics and diagnosticcs for cardiovascular diseases 35Patents top 23%Funding top 30%Innovation top 32%Moat top 32% All 8 signals ▾Patentstop 23% Fundingtop 30% Innovationtop 32% Moattop 32% Talentbottom 49% Globalbottom 40% Marketbottom 28% Techbottom 28% Patents: 88 patents matched (strict assignee match) · 63 filings since 2022 vs 25 in 2017-21 Funding: Raised $30.7M across 3 rounds · 3 rounds over 8 yrs (0.4/yr) rank vs industry peers · Fliar Intelligence Index 35/100 | $31M | 7 mo ago | — | Andreas Bergmann Managing Director | WordPressMySQLPHP+9 | — | 88 patents DPP3-targeted therapeutics for shock, oxidative stress, and myocardial protection | 1 partnership |
| 16 | CPTx Developer of programmable DNA therapeutics for a range of medical challenges 40Growth top 35%Funding top 37%Moat top 38%Talent top 38% All 9 signals ▾Growthtop 35% Fundingtop 37% Moattop 38% Talenttop 38% Techtop 46% Patentstop 50% Innovationbottom 43% Globalbottom 31% Marketbottom 25% Growth: Fresh capital in last 24 mo Funding: Raised $29.0M across 1 rounds · 1 rounds over 2 yrs (0.5/yr) rank vs industry peers · Fliar Intelligence Index 40/100 | $29M | 20 mo ago | — | Christian Sigl Founder & CTO | WordPressMySQLPHP+19 | — | 4 patents Peptide and nucleic‑acid therapeutic formulations and delivery methods | — |
| 17 | Ethris Developer of mRNA therapeutics for infectious diseases 55Patents top 25%Talent top 28%Moat top 29%Product top 30% All 11 signals ▾Patentstop 25% Talenttop 28% Moattop 29% Producttop 30% Innovationtop 35% Fundingtop 36% Growthtop 48% Techbottom 48% Marketbottom 44% Globalbottom 42% Newsbottom 27% Patents: 387 patents matched (strict assignee match) · 116 filings since 2022 vs 192 in 2017-21 Talent: Analyst team rating 4/5 rank vs industry peers · Fliar Intelligence Index 55/100 | $26M | 13 mo ago | 49 49 → 34 (-31%) | — | JimdoApple iCloud MailMicrosoft 365+10 | — | 387 patents mRNA therapeutics composition, manufacturing, and stabilization technologies | — |
| 18 | Evotec AI-driven life science company accelerating drug discovery and development 91Talent top 18%Funding top 21%Fin. health top 21%Patents top 26% All 13 signals ▾Talenttop 18% Fundingtop 21% Fin. healthtop 21% Patentstop 26% Newstop 26% Markettop 27% Partnerstop 28% Moattop 29% Techtop 33% Growthtop 35% Globaltop 35% Innovationtop 40% AItop 45% Talent: Analyst team rating 4/5 · 13 leadership moves in 12 mo Funding: Raised $25.0M across 16 rounds · 16 rounds over 28 yrs (0.6/yr) rank vs industry peers · Fliar Intelligence Index 91/100 | $25M | 5 mo ago | 252 | — | Apple iCloud MailMicrosoft 365Svelte+22 | 44 signals ▼24% Earnings · Leadership · Acquisition | 363 patents Small‑molecule therapeutics targeting oncology, infectious diseases, and fibrosis via tetrahydrothiazepine scaffolds | 1 launch · 1 award |
| 19 | Tacalyx Developer of therapeutic agents for cancer treatment 16News top 32%Growth top 35%Funding top 37%Moat top 47% All 9 signals ▾Newstop 32% Growthtop 35% Fundingtop 37% Moattop 47% Patentsbottom 38% Globalbottom 37% Marketbottom 25% Techbottom 23% Innovationbottom 21% News: 4 BI events in 12 mo (of 6 tracked, 2 types) · Top themes: Leadership, Funding Growth: Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 16/100 | $23M | 1 mo ago | 9 | — | PHPCKEditorGoogle Maps+11 | 4 signals Leadership · Funding | 2 patents Glycoengineered therapeutic antibodies targeting Globo H cancer antigens | — |
| 20 | DISCO Pharmaceuticals Developer of target-directed therapeutic modalities for the treatment of cancer 40Growth top 28%Funding top 36%News top 36%Talent top 38% All 9 signals ▾Growthtop 28% Fundingtop 36% Newstop 36% Talenttop 38% Partnerstop 40% Moattop 42% Globalbottom 39% Marketbottom 35% Techbottom 17% Growth: Web rank 50,000,000 → 10,000,000 YoY · Fresh capital in last 24 mo Funding: Raised $21.9M across 2 rounds · 2 rounds over 2 yrs (1.0/yr) rank vs industry peers · Fliar Intelligence Index 40/100 | $22M | 6 mo ago | — | Johannes Heuckmann Chief Operating Officer (COO) and founder | WordPressMySQLPHP+9 | 3 signals Contracts · Funding | — | — |
| 21 | T-CURX Developer of immune-based cancer treatments with T-cells 27Funding top 40%Moat top 45%Patents bottom 49%Talent bottom 49% All 6 signals ▾Fundingtop 40% Moattop 45% Patentsbottom 49% Talentbottom 49% Globalbottom 40% Innovationbottom 36% Funding: Raised $21.4M across 2 rounds · 2 rounds over 8 yrs (0.2/yr) Moat: Editorial + unicorn rating 4/10 · IP moat: 5 patents rank vs industry peers · Fliar Intelligence Index 27/100 | $21M | 6 mo ago | — | Christian Sollner Founder | — | — | 5 patents Non‑viral gene delivery vectors and engineered immune cells for therapeutic applications | — |
| 22 | Leon-nanodrugs Developer of technology for manufacturing lipid and polymeric nanoparticles for therapeutics 32Product top 21%Patents top 24%Innovation top 26%Moat top 32% All 10 signals ▾Producttop 21% Patentstop 24% Innovationtop 26% Moattop 32% Fundingtop 39% Talentbottom 49% Globalbottom 40% Techbottom 39% Newsbottom 21% Marketbottom 20% Product: 9 distinct product lines · Company stage: Series D Patents: 93 patents matched (strict assignee match) · 73 filings since 2022 vs 20 in 2017-21 rank vs industry peers · Fliar Intelligence Index 32/100 | $20M | 22 mo ago | 8 | Comelia Beier Co-Founder | WordPressMySQLPHP+18 | — | 93 patents Microfluidic aseptic mixing and disposable reactors for lipid nanoparticle drug production | — |
| 23 | DiaMonTech Developer of non-invasive blood glucose monitoring technology 53Talent top 23%Moat top 25%Innovation top 31%Patents top 34% All 10 signals ▾Talenttop 23% Moattop 25% Innovationtop 31% Patentstop 34% Fundingtop 35% Growthtop 45% Globalbottom 42% Techbottom 38% Marketbottom 34% Newsbottom 22% Talent: 5 named leaders on record · 5 C-suite/founder profiles curated Moat: Editorial + unicorn rating 7/10 · IP moat: 92 patents rank vs industry peers · Fliar Intelligence Index 53/100 | $19M | 19 mo ago | 29 | Werner Mäntele Co-Founder & Head Of Research And Development | WebflowYouTubecore-js+10 | — | 92 patents Optical spectroscopy devices for in‑tissue analyte detection and concentration monitoring | 1 internship |
| 24 | Mindpeak Provider of AI-based pathological analysis platform 48AI top 20%Funding top 35%Patents top 42%Moat top 42% All 9 signals ▾AItop 20% Fundingtop 35% Patentstop 42% Moattop 42% Innovationtop 43% Talentbottom 49% Techbottom 41% Globalbottom 39% Marketbottom 34% AI: Classified as an AI company · Holds AI/ML patents (G06N-family CPC) Funding: Raised $18.3M across 4 rounds · 4 rounds over 7 yrs (0.6/yr) rank vs industry peers · Fliar Intelligence Index 48/100 | $18M | 20 mo ago | 28 | Felix Faber Co-Founder & CEO | WebflowThree.jsGSAP+15 | — | 7 patents Patents concentrated in computing, sensing & instrumentation | — |
| 25 | Mainz BioMed Provider of diagnostic kits for colorectal cancer 40Funding top 36%Tech top 45%News top 47%Patents top 48% All 10 signals ▾Fundingtop 36% Techtop 45% Newstop 47% Patentstop 48% Marketbottom 49% Moatbottom 49% Talentbottom 49% Innovationbottom 46% Growthbottom 42% Globalbottom 32% Funding: Raised $17.3M across 2 rounds · 2 rounds over 3 yrs (0.7/yr) Tech: 35 technologies across 3/8 capability areas · Cloud: Cloudflare rank vs industry peers · Fliar Intelligence Index 40/100 | $17M | 4 mo ago | 64 | Guido Baechler CEO | WordPressMySQLPHP+32 | 5 signals ▼62% Funding · Announcements · Earnings | 7 patents Predictive biomarkers for colorectal adenoma and cancer progression risk assessment | 2 launchs · 1 partnership · 1 expansion |
| 26 | NeuroCare Group Provider of noninvasive neurotechnology and personalized mental healthcare platform 48Tech top 29%Growth top 37%Moat top 39%Funding top 40% All 10 signals ▾Techtop 29% Growthtop 37% Moattop 39% Fundingtop 40% Patentstop 44% Talentbottom 49% Innovationbottom 48% Globalbottom 39% Marketbottom 34% Newsbottom 18% Tech: 48 technologies across 5/8 capability areas · Cloud: Cloudflare Growth: 1 acquisition/expansion move in 24 mo · Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 48/100 | $17M | 16 mo ago | 14 | Thomas Mechtersheimer Founder & CEO | Cart FunctionalityWooCommerceWordPress+28 | — | 9 patents Adaptive transcranial stimulation systems integrating real-time physiological feedback for personalized therapy | 1 partnership |
| 27 | MODAG Developer of therapeutics and diagnostics for neurodegenerative diseases 32Moat top 25%Patents top 34%Funding top 40%Innovation top 42% All 7 signals ▾Moattop 25% Patentstop 34% Fundingtop 40% Innovationtop 42% Talentbottom 49% Globalbottom 40% Marketbottom 30% Moat: Editorial + unicorn rating 7/10 · IP moat: 27 patents Patents: 27 patents matched (strict assignee match) · 25 filings since 2022 vs 2 in 2017-21 rank vs industry peers · Fliar Intelligence Index 32/100 | $16M | 6 mo ago | 12 | Torsten Matthias CEO | — | — | 27 patents Small-molecule diphenyldiazole agents for alpha‑synuclein diagnostics and therapeutics | — |
| 28 | StratifAI Developer of multimodal artificial intelligence models to improve cancer diagnosis and treatment 55Talent top 28%AI top 30%Funding top 32%Tech top 42% All 7 signals ▾Talenttop 28% AItop 30% Fundingtop 32% Techtop 42% Growthtop 45% Globalbottom 39% Marketbottom 29% Talent: 4 named leaders on record · 4 C-suite/founder profiles curated AI: Classified as an AI company · Product described with: artificial intelligence rank vs industry peers · Fliar Intelligence Index 55/100 | $16M | 8 mo ago | — | Firas Khader CTO & Co-founder | WordPressApple iCloud MailMicrosoft 365+25 | — | — | — |
| 29 | mbiomics Provider of a genomic-based platform for microbiome-based therapeutics development 21Funding top 39%Patents top 39%Moat top 42%Innovation top 50% All 6 signals ▾Fundingtop 39% Patentstop 39% Moattop 42% Innovationtop 50% Globalbottom 36% Marketbottom 26% Funding: Raised $14.0M across 2 rounds · 2 rounds over 3 yrs (0.7/yr) Patents: 13 patents matched (strict assignee match) · 13 filings since 2022 vs 0 in 2017-21 rank vs industry peers · Fliar Intelligence Index 21/100 | $14M | 1 mo ago | 7 | — | — | — | 13 patents RNA purification methods and microbiome analysis/composition technologies for diagnostic applications | — |
| 30 | LenioBio Provider of kit for cell-free protein expression for accelerating drug delivery 50Talent top 28%Funding top 37%Moat top 37%Tech top 39% All 10 signals ▾Talenttop 28% Fundingtop 37% Moattop 37% Techtop 39% Patentstop 41% Growthtop 45% Innovationtop 47% Globalbottom 39% Marketbottom 33% Newsbottom 22% Talent: 3 named leaders on record · 3 C-suite/founder profiles curated Funding: Raised $13.0M across 6 rounds · 6 rounds over 7 yrs (0.9/yr) rank vs industry peers · Fliar Intelligence Index 50/100 | $13M | 10 mo ago | 18 18 → 44 (+144%) | Remberto Martis Founder & CEO | WordPress Block EditorElementorWordPress+30 | — | 20 patents High-throughput membrane protein ligand screening and advanced cell-free protein synthesis platforms | 1 launch · 1 partnership |
| 31 | Kupando Developer of immunotherapeutics for cancer 11News top 32%Funding top 40%Moat top 48%Talent bottom 41% All 6 signals ▾Newstop 32% Fundingtop 40% Moattop 48% Talentbottom 41% Globalbottom 37% Marketbottom 23% News: 4 BI events in 12 mo (of 4 tracked, 2 types) · Top themes: Funding, Leadership Funding: Raised $12.6M across 2 rounds · 2 rounds over 4 yrs (0.5/yr) rank vs industry peers · Fliar Intelligence Index 11/100 | $13M | 3 mo ago | 5 | Johanna Holldack Founder & CEO | — | 4 signals Funding · Leadership | — | — |
| 32 | Apheris Provider of data analytics solutions for life science industry 53AI top 20%Growth top 35%Talent top 38%Funding top 39% All 10 signals ▾AItop 20% Growthtop 35% Talenttop 38% Fundingtop 39% Partnerstop 41% Techbottom 43% Globalbottom 39% Moatbottom 38% Marketbottom 30% Newsbottom 18% AI: Classified as an AI company Growth: Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 53/100 | $12M | 17 mo ago | 19 | Robin Rohm Co-Founder & CEO & MD | DatoCMSNode.jsUnoCSS+10 | — | — | — |
| 33 | Audiocure Drug development for hearing disorders with a high unmet medical need 16Growth top 45%Funding top 47%Talent bottom 49%Global bottom 37% All 6 signals ▾Growthtop 45% Fundingtop 47% Talentbottom 49% Globalbottom 37% Techbottom 22% Marketbottom 20% Growth: Web rank 5,000,000 → 10,000,000 YoY · Fresh capital in last 24 mo Funding: Raised $9.6M across 1 rounds · 1 rounds over 14 yrs (0.1/yr) rank vs industry peers · Fliar Intelligence Index 16/100 | $10M | 16 mo ago | 7 | Reimar Schlingensiepen CEO | WordPressMySQLPHP+13 | — | — | — |
| 34 | Akribion Therapeutics Developer of RNA-guided technology with applications in cancer therapy and other indications 16Talent top 28%Funding top 47%Global bottom 48%Market bottom 25% All 5 signals ▾Talenttop 28% Fundingtop 47% Globalbottom 48% Marketbottom 25% Techbottom 18% Talent: 3 named leaders on record · 3 C-suite/founder profiles curated Funding: Raised $8.2M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) rank vs industry peers · Fliar Intelligence Index 16/100 | $8M | 16 mo ago | — | Michael Krohn Co-Founder & Co-CEO | WordPressApple iCloud MailMicrosoft 365+10 | — | — | — |
| 35 | Cellbricks Therapeutics Developer of implantable tissue therapeutics using biofabrication 50Growth top 28%Talent top 28%Global top 42%Funding bottom 49% All 6 signals ▾Growthtop 28% Talenttop 28% Globaltop 42% Fundingbottom 49% Techbottom 49% Marketbottom 31% Growth: Web rank 50,000,000 → 10,000,000 YoY · Fresh capital in last 24 mo Talent: 4 named leaders on record · 4 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 50/100 | $8M | 2 mo ago | — | Alexander Thomas Co-Founder | WordPressMySQLPHP+19 | — | — | 1 partnership · 1 award |
| 36 | Semalytix Provider of an AI based data analytics solution for reserachers 64AI top 22%Growth top 28%Funding top 36%Talent top 41% All 8 signals ▾AItop 22% Growthtop 28% Fundingtop 36% Talenttop 41% Moattop 48% Techbottom 46% Marketbottom 44% Globalbottom 37% AI: Classified as an AI company · Product described with: ai based, ai-based, artificial intelligence Growth: Headcount 54 → 67 (+24%) across vintages · Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 64/100 | $8M | 7 mo ago | 67 67 → 44 (-34%) | Janik Jaskolski Chief Product Officer | WordPressMySQLPHP+20 | — | — | — |
| 37 | Brainlab Software and integrated solutions for surgical and radiotherapy applications 82Fin. health top 18%Patents top 19%Innovation top 27%Tech top 28% All 12 signals ▾Fin. healthtop 18% Patentstop 19% Innovationtop 27% Techtop 28% Markettop 29% Moattop 29% Partnerstop 41% Fundingtop 43% Globaltop 45% Producttop 46% Growthtop 50% Newsbottom 23% Fin. health: Revenue ~$459M · Revenue +18% YoY Patents: 2,839 patents matched (strict assignee match) · 676 filings since 2022 vs 939 in 2017-21 rank vs industry peers · Fliar Intelligence Index 82/100 | $7M | 18 mo ago | 348 | — | SentryApple iCloud MailNode.js+18 | — | 2,839 patents Image-guided neurosurgery, radiation therapy planning, and AI-driven medical imaging analysis | 3 launchs |
| 38 | CertHub Provider of quality management system and documentation solutions for medical device manufacturers 32Talent top 38%Funding top 40%Market bottom 37%Global bottom 36% All 4 signals ▾Talenttop 38% Fundingtop 40% Marketbottom 37% Globalbottom 36% Talent: 2 named leaders on record · 2 C-suite/founder profiles curated Funding: Raised $7.3M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) rank vs industry peers · Fliar Intelligence Index 32/100 | $7M | 5 mo ago | — | Nicolas Gehring Co-Founder & CTO | — | — | — | — |
| 39 | Cellbox Solutions Provider of a portable device for cells storage and transport purposes 40Talent top 28%Moat top 38%Funding top 40%Tech top 44% All 11 signals ▾Talenttop 28% Moattop 38% Fundingtop 40% Techtop 44% Growthtop 45% Productbottom 48% Newsbottom 42% Globalbottom 42% Patentsbottom 39% Marketbottom 36% Innovationbottom 35% Talent: Analyst team rating 4/5 Moat: Editorial + unicorn rating 5/10 · IP moat: 11 patents rank vs industry peers · Fliar Intelligence Index 40/100 | $7M | 3 mo ago | 22 | — | ZURB FoundationYouTubeVue.js+22 | — | 11 patents Automated cell culture incubation devices and methods for bioprocessing | 1 launch · 1 partnership |
| 40 | Ovo Labs Developer of therapeutics designed to improve the quality of human eggs 37Talent top 28%Growth top 45%Funding top 48%Global bottom 45% All 6 signals ▾Talenttop 28% Growthtop 45% Fundingtop 48% Globalbottom 45% Techbottom 42% Marketbottom 31% Talent: 3 named leaders on record · 3 C-suite/founder profiles curated Growth: Web rank 10,000,000 → 50,000,000 YoY · Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 37/100 | $5M | 13 mo ago | — | Oleksandr Yagensky Co-Founder & Co-CEO | Cart FunctionalitySquarespace CommerceSquarespace+14 | — | — | 2 awards |
| 41 | Sedivention Developer of a minimally invasive cryo-ablation therapy for obesity. 22Talent top 38%Funding top 43%Moat top 45%Market bottom 37% All 7 signals ▾Talenttop 38% Fundingtop 43% Moattop 45% Marketbottom 37% Patentsbottom 33% Globalbottom 33% Innovationbottom 29% Talent: 2 named leaders on record · 2 C-suite/founder profiles curated Funding: Raised $4.2M across 2 rounds · 2 rounds over 2 yrs (1.0/yr) rank vs industry peers · Fliar Intelligence Index 22/100 | $4M | 1 mo ago | — | André Burch Co-Founder | — | — | 2 patents Cryogenic ablation tools for minimally invasive tumor destruction | — |
| 42 | Umlaut.bio Developer of small-molecule therapeutics for cancer 32Growth top 35%Funding top 44%Talent bottom 49%Tech bottom 48% All 6 signals ▾Growthtop 35% Fundingtop 44% Talentbottom 49% Techbottom 48% Globalbottom 37% Marketbottom 25% Growth: Fresh capital in last 24 mo Funding: Raised $3.5M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) rank vs industry peers · Fliar Intelligence Index 32/100 | $4M | 3 mo ago | — | Karsten Fischer CEO | WordPressPleskMySQL+29 | — | — | — |
| 43 | Cellbyte AI-driven analytics platform that enables pricing and market access professionals in the pharmaceutical… 40Talent top 28%AI top 35%Funding top 39%Global bottom 48% All 6 signals ▾Talenttop 28% AItop 35% Fundingtop 39% Globalbottom 48% Techbottom 43% Marketbottom 25% Talent: 3 named leaders on record · 3 C-suite/founder profiles curated AI: Product described with: ai-driven, natural language processing rank vs industry peers · Fliar Intelligence Index 40/100 | $3M | 6 mo ago | — | Felix Steinbrenner Co-Founder | Framer SitesApple iCloud MailGoogle Workspace+9 | — | — | — |
| 44 | Efferon Developer of extracorporeal blood purification technologies 19Patents top 45%Innovation top 49%Talent bottom 49%Funding bottom 47% All 7 signals ▾Patentstop 45% Innovationtop 49% Talentbottom 49% Fundingbottom 47% Globalbottom 46% Techbottom 30% Marketbottom 25% Patents: 6 patents matched (strict assignee match) · 6 filings since 2022 vs 0 in 2017-21 Innovation: 6 patents (top 91% of patent-holders) · 6 filings since 2022 vs 0 in 2017-21 rank vs industry peers · Fliar Intelligence Index 19/100 | $3M | 0 mo ago | — | Alexei Morozov Co-Founder | WordPressMySQLPHP+17 | — | 6 patents Polymeric sorbents for selective ion removal in water treatment processes | 1 partnership |
| 45 | SenseUP Developer of microbial production strains 21Talent top 35%Moat top 38%Patents top 49%Funding bottom 45% All 7 signals ▾Talenttop 35% Moattop 38% Patentstop 49% Fundingbottom 45% Globalbottom 40% Innovationbottom 37% Marketbottom 23% Talent: 4 named leaders on record Moat: Editorial + unicorn rating 5/10 · IP moat: 14 patents rank vs industry peers · Fliar Intelligence Index 21/100 | $3M | 12 mo ago | 10 10 → 13 (+30%) | Gunter Festel Co-Founder | — | — | 14 patents RNA synthesis platforms and aptamer‑based biosensors for diagnostic protein detection | — |
| 46 | Evanium Developer of selective alcohol antagonist 10Talent top 28%Funding bottom 46%Global bottom 29%Tech bottom 24% All 5 signals ▾Talenttop 28% Fundingbottom 46% Globalbottom 29% Techbottom 24% Marketbottom 20% Talent: 3 named leaders on record · 3 C-suite/founder profiles curated Funding: Raised $2.6M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) rank vs industry peers · Fliar Intelligence Index 10/100 | $3M | 2 mo ago | 5 | David Ofner Co-Founder | WordPressMySQLPHP+17 | — | — | 1 launch · 1 award |
| 47 | RAYDIAX Developer of therapy-assist CT system for minimally invasive interventions 24Talent top 23%Funding top 41%Global bottom 32%Market bottom 26% All 4 signals ▾Talenttop 23% Fundingtop 41% Globalbottom 32% Marketbottom 26% Talent: 5 named leaders on record · 5 C-suite/founder profiles curated Funding: Raised $2.5M across 3 rounds · 3 rounds over 3 yrs (1.0/yr) rank vs industry peers · Fliar Intelligence Index 24/100 | $3M | 3 mo ago | 9 | Tim Pfeiffer Co-Founder | — | — | — | 1 job opening · 1 award |
| 48 | brainjo AI based plafrom providing cognitive training 21AI top 35%Funding top 44%Talent bottom 49%Product bottom 45% All 7 signals ▾AItop 35% Fundingtop 44% Talentbottom 49% Productbottom 45% Globalbottom 32% Techbottom 31% Marketbottom 22% AI: Product described with: ai based, ai-based Funding: Raised $2.4M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) rank vs industry peers · Fliar Intelligence Index 21/100 | $2M | 1 mo ago | — | Christian Gnerlich Founder | MyWebsiteDudaMyWebsite Creator+10 | — | — | — |
| 49 | smartbax Developer of multi-targeted antibacterial compounds 14Talent top 38%News top 43%Moat top 48%Funding top 49% All 6 signals ▾Talenttop 38% Newstop 43% Moattop 48% Fundingtop 49% Globalbottom 32% Marketbottom 22% Talent: 2 named leaders on record · 2 C-suite/founder profiles curated News: 2 BI events in 12 mo (of 3 tracked, 1 types) · Top themes: Funding rank vs industry peers · Fliar Intelligence Index 14/100 | $2M | 7 mo ago | 3 | Stephan Sieber Co-Founder | — | — | — | — |
| 50 | Insellar Developer of minimally invasive brain interfaces for mental health treatment 32Talent top 38%Funding top 49%Global bottom 33% All 3 signals ▾Talenttop 38% Fundingtop 49% Globalbottom 33% Talent: 2 named leaders on record · 2 C-suite/founder profiles curated Funding: Raised $469k across 1 rounds · 1 rounds over 1 yrs (1.0/yr) rank vs industry peers · Fliar Intelligence Index 32/100 | $469K | 2 mo ago | — | Selina Greuel Co-Founder & CCO | — | — | — | — |
Top 12 Life Sciences companies in Germany
#1
Series D · Aschheim, Bavaria · founded 2013 · 12 employees$102.8Mraised▾
Series D · Aschheim, Bavaria · founded 2013 · 12 employees
{}
Fliar Intelligence Index™ 27how this company ranks against its industry peers
Funding
top 21%Growth
top 35%Moat
top 36%Global
bottom 47%Patents
bottom 42%Innovation
bottom 36%Funding: Raised $103M across 5 rounds · 5 rounds over 8 yrs (0.6/yr) · Last round Conventional Debt (Jan 2026)
Growth: Fresh capital in last 24 mo
Moat: Editorial + unicorn rating 4/10 · IP moat: 21 patents · Soonicorn
Funding rounds
- Jan 2026Conventional Debt$23.3M
- Jul 2024Series D$50M
- Sep 2022Series C$52.8M
- Nov 2021Grant (prize money)$56.4K
Investors
EIC Fund, Europa, 415 CAPITAL, Andera Partners, BioMedPartners, Credit Mutuel Equity
Tech stack
DrupalJqueryNginxPhpPleskPwa
#2
Series E · Munich, Bavaria · founded 2004 · 54 employees$681Mraised▾
Series E · Munich, Bavaria · founded 2004 · 54 employees
Developer of radiopharmaceuticals and radioisotopes for cancer treatment. The company's lead product is radionuclide therapy candidate LuCaFab (ITM-31) for the treatment of malignant brain tumors. The company offers medical isotopes like EndolucinBeta and TOCscan. It also offers radiolabelling and quality control equipment like iQS - Theranostics Synthesizer, iQS Ga-68, Fluidic Labeling, Module Reagent Set Manual, and 177Lu Labeling.
Fliar Intelligence Index™ 27how this company ranks against its industry peers
Funding
top 25%Growth
top 35%Moat
top 42%Global
top 48%Talent
top 50%Market
bottom 38%Funding: Raised $681M across 8 rounds · 8 rounds over 17 yrs (0.5/yr) · Last round Conventional Debt (May 2025)
Growth: Fresh capital in last 24 mo
Moat: Editorial + unicorn rating 5/10 · Soonicorn · 10 curated direct competitors tracked
Audience (LinkedIn): 24k LinkedIn followers — 3.1% of this cohort's audience
Activity (LinkedIn): 1 awards announced in 12 mo
Funding rounds
- May 2025Conventional Debt$262.5M
- Jun 2024Series E$204.4M
- Jun 2023Series E$273M
- Mar 2022Series D$36.4M
Founders & team
Investors
Temasek, BlackRock, Qatar Investment Authority, Carbyne Equity Partners, ATHOS, European Investment Bank
Tech stack
Apache Http ServerBootstrapIonosJqueryLightboxMatomo Analytics
#3
Acquired · Munich, Bavaria · founded 2015 · 33 employees$214.1Mraised▾
Acquired · Munich, Bavaria · founded 2015 · 33 employees
Developer of antibody-drug conjugates for the treatment of cancer. The company has proprietary technology platforms which include the Tub-tag conjugation platform, P5 conjugation platform, and Topoisomerase-I inhibitor platform to develop antibody-drug conjugates for solid and hematological tumors. It offers TUB-040 for ovarian and non-small cell lung cancer. TUB-030, TUB-050, and TUB-060 for solid tumors.
Fliar Intelligence Index™ 60how this company ranks against its industry peers
News
top 15%Funding
top 18%Growth
top 20%Patents
top 27%Moat
top 28%Innovation
top 35%News: 13 BI events in 12 mo (of 21 tracked, 3 types) · +333% YoY · 12 high-value events (IPO/M&A/funding/contracts) in 12 mo
Funding: Raised $214M across 5 rounds · 5 rounds over 6 yrs (0.8/yr) · Last round Series C (Oct 2025)
Growth: Web rank 10,000,000 → 5,000,000 YoY · Fresh capital in last 24 mo
Audience (LinkedIn): 18k LinkedIn followers — 2.3% of this cohort's audience
Activity (LinkedIn): 1 awards announced in 12 mo
Funding rounds
- Oct 2025Series C$401M
- Mar 2024Series B$138.8M
- Aug 2022Grant (prize money)—
- May 2022Series B$63.1M
Founders & team
Investors
Nextech Invest, Deep Track Capital, Frazier Life Sciences, Andera Partners, BioMedPartners, Bayern Kapital
Tech stack
All-InklApache Http ServerBorlabs CookieCore-JsElementorJquery
#4
Seed · Berlin, Berlin · founded 2018 · 9 employees$22.8Mraised▾
Seed · Berlin, Berlin · founded 2018 · 9 employees
Tacalyx is developing therapeutic agents for cancer treatment. The lead products are developed to target cancer-specific carbohydrate antigens that are located on the surface of metastatic malignant tumors (TACAs and other related cell surface glycans).
Fliar Intelligence Index™ 16how this company ranks against its industry peers
News
top 32%Growth
top 35%Funding
top 37%Moat
top 47%Patents
bottom 38%Global
bottom 37%News: 4 BI events in 12 mo (of 6 tracked, 2 types) · Top themes: Leadership, Funding
Growth: Fresh capital in last 24 mo
Funding: Raised $22.8M across 3 rounds · 3 rounds over 7 yrs (0.4/yr) · Last round Seed (Apr 2026)
Audience (LinkedIn): 3k LinkedIn followers
Activity (LinkedIn): 1 partnerships (incl. Biotechnology Innovation Organization (BIO)) announced in 12 mo
Funding rounds
- Apr 2026Seed$12.9M
- Jun 2024Seed$15.1M
- Sep 2019Seed$7.7M
Investors
Boehringer Ingelheim Venture Fund, Kurma Partners, Creathor Venture, Coparion, Idinvest Partners, HTGF
Tech stack
Closure LibraryGoogle Font ApiIonosLit-ElementLit-HtmlMicrosoft 365
#5
Public · Halle, Saxony Anhalt · founded 1997 · 100 employees$112.2Mraised▾
Public · Halle, Saxony Anhalt · founded 1997 · 100 employees
Vivoryon Therapeutics is developing therapeutic agents for treating age-related diseases. The company leading candidate is PQ912 is in phase 2a of the clinical trial and is for Alzheimer's disease and Cancer, other candidates of the company are PQxxx and PQ1565 which is in the preclinical stage and effective against cancer and other diseases. Theses are small molecule-based and inhibit QTCPL. The company has developed glutaminyl cyclase enzyme inhibitors which is a key enzyme in Alzheimer’s disease and cancer.
Fliar Intelligence Index™ 45how this company ranks against its industry peers
Funding
top 19%News
top 29%Growth
top 47%Market
top 49%Talent
bottom 49%Global
bottom 39%Funding: Raised $112M across 5 rounds · 5 rounds over 11 yrs (0.5/yr) · Last round Post IPO (Oct 2025)
News: 4 BI events in 12 mo (of 6 tracked, 3 types) · Top themes: Earnings, Funding
Growth: Headcount 100 → 100 (+0%) across vintages · Fresh capital in last 24 mo
Audience (LinkedIn): 2k LinkedIn followers
Funding rounds
- Oct 2025Post IPO$6M
- May 2023Post IPO$26.8M
- Oct 2019Post IPO$47.8M
- Oct 2016Post IPO$16.7M
Founders & team
Investors
Andera Partners, Bmp Ventures, IBG Beteiligungsgesellschaft Sachsen-Anhalt, Life Sciences Partners, HBM Partners, EQT
Tech stack
All-InklContact Form 7CookieyesJqueryJquery MigrateJquery Ui
#6
Series A · Munich, Bavaria · founded 2020 · 7 employees$14Mraised▾
Series A · Munich, Bavaria · founded 2020 · 7 employees
Provider of a genomic-based platform for microbiome-based therapeutics development. It offers platforms that combine DNA and RNA analysis for single or molecule detection which includes GOLD for microbiome analysis, monitors to track microbiome modulation, and STRATOS for microbiome profiling.
Fliar Intelligence Index™ 21how this company ranks against its industry peers
Funding
top 39%Patents
top 39%Moat
top 42%Innovation
top 50%Global
bottom 36%Market
bottom 26%Funding: Raised $14.0M across 2 rounds · 2 rounds over 3 yrs (0.7/yr) · Last round Series A (Apr 2026)
Patents: 13 patents matched (strict assignee match) · 13 filings since 2022 vs 0 in 2017-21 · Latest publication 2026
Moat: Editorial + unicorn rating 4/10 · IP moat: 13 patents · 9 curated direct competitors tracked
Audience (LinkedIn): 10k LinkedIn followers
Funding rounds
- Apr 2026Series A$14.1M
- Mar 2023Series A$14M
Investors
Bayern Kapital, HTGF, MIG Fonds
#7
Public · Hamburg, Hamburg · founded 1993 · 252 employees$25Mraised▾
Public · Hamburg, Hamburg · founded 1993 · 252 employees
AI-driven life science company accelerating drug discovery and development. It is focused on pioneering drug discovery and preclinical development using advanced technologies, deep disease expertise, and integrated R&D platforms. It accelerates the creation of new therapies across modalities, including small molecules and biologics, to bring life-changing medicines to patients faster.
Fliar Intelligence Index™ 91how this company ranks against its industry peers
Talent
top 18%Funding
top 21%Fin. health
top 21%Patents
top 26%News
top 26%Market
top 27%Talent: Analyst team rating 4/5 · 13 leadership moves in 12 mo
Funding: Raised $25.0M across 16 rounds · 16 rounds over 28 yrs (0.6/yr) · Last round Grant (prize money) (Jan 2026)
Fin. health: Revenue ~$863M (FY2017) · Net margin 2.6% · Revenue 34.5x total funding
Audience (LinkedIn): 124k LinkedIn followers — 16.2% of this cohort's audience
Activity (LinkedIn): 1 product launches · 1 awards announced in 12 mo
Funding rounds
- Jan 2026Grant (prize money)—
- May 2025Grant (prize money)$2.5M
- Apr 2025Grant (prize money)$654.4K
- Jun 2023Grant (prize money)$1.7M
Investors
Gates, Second Genome, LAB282, Europa, Bmbf, IFB Hamburg
Tech stack
Amazon S3Amazon Web ServicesApple Icloud MailCloudflareCloudflare Bot ManagementCookiebot
#8
Series A · Schonefeld, Brandenburg · founded 2018 · 5 employees$12.6Mraised▾
Series A · Schonefeld, Brandenburg · founded 2018 · 5 employees
Developer of immunotherapeutics for cancer. It offers a lead candidate KUP101 an immunostimulatory agent co-encapsulated in a liposomal formulation for the treatment of solid tumors in combination with other drugs.
Fliar Intelligence Index™ 11how this company ranks against its industry peers
News
top 32%Funding
top 40%Moat
top 48%Talent
bottom 41%Global
bottom 37%Market
bottom 23%News: 4 BI events in 12 mo (of 4 tracked, 2 types) · Top themes: Funding, Leadership
Funding: Raised $12.6M across 2 rounds · 2 rounds over 4 yrs (0.5/yr) · Last round Series A (Mar 2026)
Moat: Editorial + unicorn rating 4/10 · 10 curated direct competitors tracked
Audience (LinkedIn): 552 LinkedIn followers
Funding rounds
- Mar 2026Series A$11.5M
- Sep 2022Series A$12.6M
Founders & team
Investors
Remiges Ventures, LifeCare Partners, Brandenburg Capital, HTGF, Ventura Biomed, CARMA FUND
#9
Public · Mainz, Rhineland-Palatinate · founded 2021 · 64 employees$17.3Mraised▾
Public · Mainz, Rhineland-Palatinate · founded 2021 · 64 employees
Provider of diagnostic kits for colorectal cancer. The company's product ColoAlert is a PCR-based molecular genetic colorectal cancer early-detection stool test. It uses proprietary methods to analyze cell DNA for specific tumor markers combined with the fecal immunochemistry test (FIT) and is designed to detect tumor DNA and CRC cases in their earliest stages.
Fliar Intelligence Index™ 40how this company ranks against its industry peers
Funding
top 36%Tech
top 45%News
top 47%Patents
top 48%Market
bottom 49%Moat
bottom 49%Funding: Raised $17.3M across 2 rounds · 2 rounds over 3 yrs (0.7/yr) · Last round Post IPO (Feb 2026)
Tech: 35 technologies across 3/8 capability areas · Cloud: Cloudflare · Security: Hsts, Http/3
News: 5 BI events in 12 mo (of 33 tracked, 5 types) · -62% YoY · 3 high-value events (IPO/M&A/funding/contracts) in 12 mo
Audience (LinkedIn): 145 LinkedIn followers
Activity (LinkedIn): 2 product launches · 1 partnerships · 1 expansions announced in 12 mo
Funding rounds
- Feb 2026Post IPO$3M
- Jun 2023Post IPO$14.3M
Founders & team
#10
Series C · Hennigsdorf, Brandenburg · founded 2013$30.7Mraised▾
Series C · Hennigsdorf, Brandenburg · founded 2013
Developer of therapeutics and diagnosticcs for cardiovascular diseases. The company is developing a targeted therapy called Procizumab to inhibit the DPP3 pathway in cardiogenic shock. It is also using a biomarker called Dipeptidyl Peptidase 3 to identify and stratify high-risk patients.
Fliar Intelligence Index™ 35how this company ranks against its industry peers
Patents
top 23%Funding
top 30%Innovation
top 32%Moat
top 32%Talent
bottom 49%Global
bottom 40%Patents: 88 patents matched (strict assignee match) · 63 filings since 2022 vs 25 in 2017-21 · Latest publication 2026
Funding: Raised $30.7M across 3 rounds · 3 rounds over 8 yrs (0.4/yr) · Last round Series C (Nov 2025)
Innovation: 88 patents (top 32% of patent-holders) · 63 filings since 2022 vs 25 in 2017-21
Audience (LinkedIn): 2k LinkedIn followers
Activity (LinkedIn): 1 partnerships (incl. UKSH and University of Lübeck) announced in 12 mo
Funding rounds
- Nov 2025Series C$63.7M
- Feb 2024Series A—
- Dec 2019Series A$7.6M
- Oct 2018Series A$23M
Founders & team
Investors
Brandenburg Capital, Wellington Partners Venture Capital, HBM Partners, Boditech Med, NRW.Bank, Deutsche Biotech Innovativ AG
#11
Seed · Berlin, Berlin · founded 2016$8.1Mraised▾
Seed · Berlin, Berlin · founded 2016
Developer of implantable tissue therapeutics using biofabrication. This company develops and produces implantable tissue therapeutics to address the limitations of current injectable cell therapies. The approach involves combining therapeutic cells with biomaterials through a proprietary light-based bioprinting platform. The resulting implantable tissues are designed to be biologically functional, immune-compatible, and optimized for surgical implantation, leading to sustainable therapeutic effects. The technology enables the creation of vascularized, complex tissue at scale.
Fliar Intelligence Index™ 50how this company ranks against its industry peers
Growth
top 28%Talent
top 28%Global
top 42%Funding
bottom 49%Tech
bottom 49%Market
bottom 31%Growth: Web rank 50,000,000 → 10,000,000 YoY · Fresh capital in last 24 mo
Talent: 4 named leaders on record · 4 C-suite/founder profiles curated
Global: Legal entities in 2 countries: Germany, United States · Investors from 3 countries beyond Germany
Audience (LinkedIn): 8k LinkedIn followers
Activity (LinkedIn): 1 partnerships · 1 awards · 1 expansions (incl. ExpoR&D | Catalzye360) announced in 12 mo
Funding rounds
- Mar 2026Seed$8.1M
Founders & team
Investors
Silicon Roundabout Ventures, SPRIND, ACT, Brooks Hill Partners
Tech stack
AstraComplianzCore-JsElementorElementor Header & Footer BuilderGoogle Analytics
#12
Seed · Munich, Bavaria · founded 2021$4.2Mraised▾
Seed · Munich, Bavaria · founded 2021
{}
Fliar Intelligence Index™ 22how this company ranks against its industry peers
Talent
top 38%Funding
top 43%Moat
top 45%Market
bottom 37%Patents
bottom 33%Global
bottom 33%Talent: 2 named leaders on record · 2 C-suite/founder profiles curated
Funding: Raised $4.2M across 2 rounds · 2 rounds over 2 yrs (1.0/yr) · Last round Seed (May 2026)
Moat: Editorial + unicorn rating 4/10 · IP moat: 2 patents
Audience (LinkedIn): 449 LinkedIn followers
Activity (LinkedIn): 1 expansions announced in 12 mo
Funding rounds
- May 2026Seed$3.4M
- Nov 2024Seed$843.1K
Founders & team
Investors
HTGF, Bmp Ventures, IBG Beteiligungsgesellschaft Sachsen-Anhalt, Superangles, Cambridge Venture Partners, BioVaria
Funding & investor landscape
$10.9Btotal disclosed funding
421companies funded
997disclosed rounds
8rounds last 90 days
Most active investors
Notable founders
Oliver Buck
Founder · ITM
Steffen Schuster
CEO · ITM
Dominik Schumacher
Co-Founder & CEO · Tubulis Technologies
Jonas Helma-Smets
Co-Founder & CSO · Tubulis Technologies
Ulrich Dauer
CEO · Vivoryon
Johanna Holldack
Founder & CEO · Kupando
Guido Baechler
CEO · Mainz BioMed
Andreas Bergmann
Managing Director · 4TEEN4 Pharmaceuticals
Alexander Thomas
Co-Founder · Cellbricks Therapeutics
Tobias Lam
Co-Founder & CTO · Cellbricks Therapeutics
André Burch
Co-Founder · Sedivention
Ute Nollert
Founder & CEO · Sedivention
Prism market signals · Germany · country-scoped Prism corpus, 141,341 docs
Market landscape — 10 sub-themes by coverage
Share of Life Sciences coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
RESEARCH SIGNALS · Germany
How research on Biotechnology is moving in Germany
A read on the academic research around Biotechnology — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 1,297 Germany-affiliated papers.
research sentiment over time
200820152026
enthusiastic · positive · guarded tone
Tone is overwhelmingly optimistic and intensifying — the enthusiastic (strongly-positive) share moved 38% → 41% across 2008–2026.
top research entities
- Heidelberg University85
- German Cancer Research Center49
- Ludwig-Maximilians-Universität München48
- Technical University of Munich43
- Karlsruhe Institute of Technology33
leading researchers
Lennart Hilbert · Henry Reyer · Michael Oster · Nares Trakooljul · Badhe, Pravin · Avon Augustin Nalpadan · Siriluck Ponsuksili · Ralf Nauen
▲
Breakthroughs421 · 32%
▼ 35%→31% share
▼0.9× share momentum0 median citations78% since 2021mostly empirical
Messenger RNA research surged 1→14 papers, with Genome and RNA polymerase II newly emerging, signaling intensifying transcription-focused discovery.
rising sub-themes (early→recent)
- Gene3→29
- Mutant3→19
- Transcription (linguistics)3→16
- Messenger RNA1→14
- Immune system1→12
Newly emergingGenome 0→15 · Mutation 0→13 · RNA polymerase II 0→9
Landmark The HCV Life Cycle: In vitro Tissue Culture Systems and Therapeutic Targets · 4,863 cites
◆
Advancements429 · 33%
33%→33% share
▲1.0× share momentum0 median citations82% since 2021mostly empirical
Downregulation/upregulation and Selection newly emerged while Agriculture tripled (2→12), reflecting rising gene-regulation and crop-biotech momentum.
rising sub-themes (early→recent)
- Gene3→20
- Agriculture2→12
- Extracellular1→11
- Immune system1→11
- Transcriptome1→9
Newly emergingDownregulation and upregulation 0→12 · Selection (genetic algorithm) 0→11 · Antibody 0→10
Landmark Regulation of the Voltage Gated K<sup>+</sup> Channel K<sub>v1.3</sub> by Recombinant Human Klot · 5,606 cites
▼
Concerns184 · 14%
▼ 17%→14% share
▼0.8× share momentum0 median citations79% since 2021mostly empirical
Antibiotic resistance and Agriculture concerns both rose sharply, with Sustainability newly flagged — resistance and ecological risks intensifying across German biotech.
rising sub-themes (early→recent)
- Antibiotic resistance2→9
- Gene1→7
- Agriculture4→9
- Antimicrobial1→4
- Microbiome1→4
Newly emergingContext (archaeology) 0→11 · Sustainability 0→9 · Production (economics) 0→7
Landmark Prebiotic effects: metabolic and health benefits · 2,037 cites
RESEARCH HOTSPOTS · Germany
Where biotechnology is researched across Germany
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Munich119 · +0.49
Berlin91 · +0.38
Heidelberg90 · +0.52
Jülich/Bonn72 · +0.41
Karlsruhe34 · +0.30
Aachen23 · +0.51
Dresden22 · +0.54
Stuttgart7 · +0.56
PATENT SIGNAL · Germany
Who's filing biotechnology patents in Germany
Germany biotechnology patent filing is cooling — 53,233 filings from 8,000 assignees (2016–2025), led by Immatics Biotechnologies, BASF Plant Science, BASF SE; annual filings 4819→4267.
53,233 filings8,000 assigneespeak 6040/yr2016–2025
filing momentum (YoY 2016–2025)
top patent filers
- Immatics Biotechnologies4875
- BASF Plant Science4000
- BASF SE3548
- Boehringer Ingelheim INT3441
- Merck Patent3137
- MAX Planck Gesellschaft1805
- Evonik Degussa1684
- Amgen RES Munich1665
Common questions
How many Life Sciences companies are there in Germany?
Radar tracks 1802 indexable Life Sciences companies headquartered in Germany that meet our profile-completeness bar.
What is the total funding raised by Life Sciences companies in Germany?
The Life Sciences companies in Germany on this list have raised a combined $10.9B in disclosed equity funding across 421 funded companies.
Which is the highest-funded Life Sciences company in Germany?
CureVac is the highest-funded Life Sciences company in Germany, with $975.3M in disclosed equity funding.
How many Life Sciences companies in Germany are funded?
421 of the 1802 Life Sciences companies in Germany on this list have disclosed at least one equity funding round.
How many Life Sciences unicorns are there in Germany?
2 Life Sciences companies in Germany on this list are valued at $1B or more.
Who are the top investors in Germany Life Sciences companies?
The most active investors in Germany Life Sciences companies on this list include Europa, HTGF, EIC Fund, Kfw, Bayern Kapital.
Riya SenguptaFinancials
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.